Crizotinib was Federal Food and Drug Administration (FDA) approved on August 26, 2011 - the first FDA-approved NSCLC personalized therapy in which treatment is determined by clinically validated ALK testing [49,111,129]. This evidence concerns the gene ALK and non-small cell lung carcinoma.